1 Network di centri specializzati ; 10 Network di progetti di ricerca ; 3 Sperimentazioni cliniche internazionali ; 1 Network di registri di pazienti ;
-
- Competence Network Paediatric Oncology and Haematology (Expert centres)
- Charité - Universitätsmedizin Berlin (CVK)
- Ulteriori informazioni
-
- DIRECT: disseminate research funded by EC improving treatment options for children suffering from cancer
- St. Anna Kinderkrebsforschung e.V.
- Ulteriori informazioni
-
- ENCCA: European Network for Cancer Research in Children and Adolescents
- St. Anna Kinderkrebsforschung e.V.
- Ulteriori informazioni
-
- GERMANIA
- Baden-Württemberg
- FREIBURG
-
- GERMANIA
- Baden-Württemberg
- MANNHEIM
-
- GERMANIA
- Baden-Württemberg
- MANNHEIM
- EUROPEAN LEUKEMIA NET: Strengthen and develop scientific and technological excellence in research and therapy of leukemia
- Universitätsklinikum Mannheim
- Ulteriori informazioni
-
- Information network for rare tumors in children and adolescents
- Universitätsklinikum Erlangen
- Ulteriori informazioni
-
- Competence Network Paediatric Oncology and Haematology (Research)
- Charité - Universitätsmedizin Berlin (CVK)
- Ulteriori informazioni
-
- RARECARE: surveillance of rare cancers in Europe
- Fondazione IRCCS Istituto Nazionale dei Tumori
- Ulteriori informazioni
-
- REGNO UNITO; GRAN BRETAGNA
- South Glamorgan
- CARDIFF
-
- REGNO UNITO; GRAN BRETAGNA
- Tyne & Wear
- NEWCASTLE UPON TYNE
- EPOC: European paediatric oncology off-patent medicines consortium
- Newcastle University
- Ulteriori informazioni
-
- PAESI BASSI
- Brabant
- BREDA
- MDS Romiplostim: A randomized, double blind, placebo controlled phase II study evaluating the efficacy and safety of Romiplostim treatment of Thrombocytopenia in subjects with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) (coordination)
- Amgen Europe B.V.
- Ulteriori informazioni
-
- SPAGNA
- Madrid
- COLMENAR VIEJO
- APL-A-005-02: Phase I - II clinical and pharmacokinetic study of Aplidin (APL) as a 3-hour intravenous infusion every 2 weeks, in children with refractory or relapsed malignant tumours and leukemia (coordination)
- PharmaMar S.A. Sociedad Unipersonal
- Ulteriori informazioni
-
- A Phase III, Multi-Center, Randomized, Controlled Study to Assess the Efficacy and Safety of ON 01910.Na Administered as a 72-Hour Continuous Intravenous Infusion Every Other Week in Myelodysplastic Syndrome Patients with Excess Blasts Relapsing After, or Refractory to, or Intolerant to Azacitidine or Decitabine (Coordination)
- Hospital Universitario La Paz
- Ulteriori informazioni
-
- GERMANIA
- Schleswig-Holstein
- LÜBECK
- GEKID: Association of the epidemiologic cancer registries
- Registerstelle Krebsregister Schleswig-Holstein
- Ulteriori informazioni
